ERBB2 and breast carcinoma: In the GSE22226, analyzing 23 luminal breast cancers, 20 HER2+, and 39 TNBC, we observed a significant downregulation of the inflammatory response‐related markers in the luminal subtype, whereas a significant upregulation was observed in the HER2+ subtype.